Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNYSE:JNJ
Date1/1978
Raised
Post IPO Valuation

General Information

Websitejnj.com
Twitter@JNJCares
CategoryBioTech
Phone732-524-0400
Employees
Founded1886
DescriptionCaring for the world.

Offices

New Brunswick, USA
One Johnson & Johnson Plaza
New Brunswick, NJ, 08933
USA

People

Chairman of the Board
Chairman, Board of Directors, Chief Executive Officer
CTO
Vice President, Finance and Chief Financial Officer
VP Global Application Services
Vice President, Global Human Resources
Vice President, General Counsel
Board Director
Show All People

Acquisitions

Total$4.52B
Aragon Pharmaceuticals, 6/2013 $1B
Calibra Medical, 7/2012
Crucell, 2/2011 $2.3B
Acclarent, 12/2009 $785M
Omrix Biopharmaceuticals, 11/2008 $433M
HealthMedia, 10/2008
BabyCenter, 3/2001

Investments

Crucell 9/2009

Service Providers

Enterprise Application

Tags

Johnson & Johnson

Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field.

Segments

The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics.

Consumer

The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON’S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON’S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women’s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world.

Pharmaceutical

The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a biologic approved for the treatment of Crohn’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL CONSTA (risperidone), a long-acting injectable, and INVEGA (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN (levofloxacin) and FLOXIN (ofloxacin), both in the anti-infective field; CONCERTA (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a novel delivery system.

Medical Devices and Diagnostics

The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon’s surgical care and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vistakon’s disposable contact lenses.

History

Johnson & Johnson was founded in 1886.

Recent Milestones

Videos

Screenshots

Products

Band-Aid
Benadryl
Clean & Clear
Listerine
Neutrogena

Stock Price

Sources

  1. Johnson & Johnson boosts cancer drug pipeline with $1-billion deal to buy Aragon Pharmaceuticals (firstwordpharma.com) [edit]
  2. J&J's LifeScan unit Acquires Calibra Medical (pevc.dowjones.com) [edit]
  3. Crucell eagerly accepts $2.3B buyout offer from J&J (fiercebiotech.com) [edit]
  4. J&J unit paying $785M for device maker Acclarent (biosciencetechnology.com) [edit]
  5. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc. (ethicon.com) [edit]
  6. Johnson & Johnson acquires Ann Arbor's software firm HealthMedia (mlive.com) [edit]
  7. Johnson & Johnson Acquires BabyCenter From eToys, Inc. Leading Online Destination for Parents Plans for Continued Expansion of Operations (investor.jnj.com) [edit]
  8. J&J grabs $443M stake in Crucell, inks flu pact (fiercebiotech.com) [edit]
  9. MGH, Johnson & Johnson to collaborate on cancer blood test (masshightech.com) [edit]
Edit This Page
Last Edited 4/9/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy